The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation

Oncogene

Volumn 26, Issue 11, 2007, Pages 1577-1585

  Pecquet, C ^a   Nyga, R ^a   Penard Lacronique, V ^b   Smithgall, T E ^c   Murakami, H ^d   Regnier A ^a   Lassoued, K ^a   Gouilleux, F ^a  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Hck; Oncogenes; Signal transduction; Src kinases; Tel Abl; Tel Jak2

Indexed keywords

ABELSON KINASE; HEMATOPOIETIC CELL KINASE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR ETV6;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-HCK; PYRIMIDINES;

EID: 33947185341     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209949     Document Type: Article

References (46)

1. Blake RA, Broome MA, Liu X, Wu J, M, Sun L et al. (2000). SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20: 9018-9027.
2. Briggs SD, Bryant SS, Jove R, Sanderson SD, Smithgall TE. (1995). The Ras GTPase-activating protein (GAP) is an SH3 domain-binding protein and substrate for the Src-related tyrosine kinase, Hck. J Biol Chem 270: 14718-14724.
3. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT et al. (2000). TEL-JAK2 transgenic mice develop T-cell leukaemia. Blood 95: 3891-3899.
4. Cazzaniga G, Tosi S, Aloisi A, Giudici G, Daniotti M, Pioltelli P et al. (1999). The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 94: 4370-4373.
5. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O. (1998). Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 91: 3734-3745.
6. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. (2004). A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279: 34227-34239.
7. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. (1996). Activation of Src kinases p53/ 56lyn and p59hck by p210bcr-abl in myeloid cells. Cancer Res 56: 3589-3596.
8. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698.
9. Dos Santos NR, Ghysdael J. (2005). A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukaemia. Leukemia 20: 182-185.
10. Ernst TJ, Slattery KE, Griffin JD. (1994). p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem 269: 5764-5769.
11. Golub TR, Barker GF, Lovett M, Gilliland DG. (1994). Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77: 307-316.
12. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK et al. (1996). Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16: 4107-4116.
13. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ et al. (1996). Discovery of a novel, potent, and Src family selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependentT cell activation. J Biol Chem 271: 695-701.
14. Ho JM, Nguyen MH, Dierov JK, Badger KM, Beattie BK, Tartaro P et al. (2002). TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 100: 1438-1448.
15. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. (2004). Requirement of Src kinases Lyn, Hck and Fgr for Bcr-Abl1-induced B-lymphoblastic leukaemia but not chronic myeloid leukaemia. Nat Genet 36: 453-461.
16. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M. (2002). Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet 138: 139-142.
17. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. (2002). The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21: 5766-5774.
18. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. (1998). A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18: 184-187.
19. Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M et al. (2001). Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12) (q22;p12). Blood 97: 1050-1055.
20. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P et al. (2000). Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95: 2076-2083.
21. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M et al. (1997). A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309-1312.
22. Lionberger JM, Wilson MB, Smithgall TE. (2000). Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl Is uppressed by kinase-defective Hck. J Biol Chem 275: 18581-18585.
23. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J et al. (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15: 3083-3090.
24. Malinge S, Monni R, Bernard O, Penard-Lacronique V. (2006). Activation of the NF-κB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of anti-apoptotic IAP proteins and involves IKKα. Oncogene 25: 3589-3597.
25. Million RP, Aster J, Gilliland DG, Van Etten RA. (2002). The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 99: 4568-4577.
26. Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. (2004). A Direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 24: 4685-4695.
27. Omura T, Sakai H, Murakami H. (2002). Acceleration of granulocyte colony-stimulating factor-induced neutrophilic nuclear lobulation by overexpression of Lyn tyrosine kinase. Eur J Biochem 269: 381-389.
28. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. (1992). Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52: 4773-4778.
29. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. (1995). The novel activation of ABL by fusion to an ets-related gene. TEL Cancer Res 55: 34-38.
30. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P et al. (1997). Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9; 15; 12) in a myeloid leukemia. Blood 90: 2535-2540.
31. Rosa Santos SC, Dumon S, Mayeux P, Gisselbrecht S, Gouilleux F. (2000). Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene 19: 1164-1172.
32. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA. (1986). Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261: 13754-13759.
33. Santos SC, Monni R, Bouchaert I, Bernard O, Gisselbrecht S, Gouilleux F et al. (2001). Involvement of the NF-ΚB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Lett 497: 148-152.
34. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. (2000). Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289: 1938-1942.
35. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS et al. (1998). Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 17: 5321-5333.
36. Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. (2002). Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 30: 262-271.
37. Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Hallek M. (2003). The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 17: 283-289.
38. Talamonti MS, Roh MS, Curley SA, Gallick GE. (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60.
39. Tatton L, Morley GM, Chopra R, Khwaja A. (2003). The Src-selective kinase knhibitor PP1 also Inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 278: 4847-4853.
40. Tatosyan AG, Mizenina OA. (2000). Kinases of the Src family: structure and functions. Biochemistry (Moscow) 65: 49-58.
41. Tilbrook PA, Palmer GA, Bittorf T, McCarthy DJ, Wright MJ, Sarna MK et al. (2001). Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn. Cancer Res 61: 2453-2458.
42. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B et al. (2001). Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 30: 274-282.
43. Voss J, Posern G, Hannemann JR, Wiedemann LM, Turhan AG, Poirel H et al. (2000). The Leukaemic Bcr-Abl et Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene 19: 1684-1690.
44. Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. (1997). The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr. J Biol Chem 272: 33260-33270.
45. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. (2003). Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101: 664-672.
46. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. (2002). Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21: 8075-8088.